Birt-Hogg-Dube´(BHD) syndrome is characterized by the development of pneumothorax, hair folliculomas and renal tumors and the responsible BHD gene is thought to be a tumor suppressor. The function of folliculin (Flcn), encoded by BHD, is totally unknown, although its interaction with Fnip1 has been reported. In this study, we identified a novel protein binding to Flcn, which is highly homologous to Fnip1, and which we named FnipL (recently reported in an independent study as Fnip2). The interaction between FnipL/Fnip2 and Flcn may be mediated mainly by the C-terminal domains of each protein as is the case for the Flcn-Fnip1 interaction. FnipL/Fnip2 and Flcn were located together in the cytoplasm in a reticular pattern, although solely expressed Flcn was found mainly in the nucleus. Cytoplasmic retention of Flcn was canceled with C-terminal truncation of FnipL/Fnip2, suggesting that FnipL/Fnip2 regulates Flcn distribution through their complex formation. By the employment of siRNA, we observed a decrease in S6K1 phosphorylation in the BHDsuppressed cell. We also observed a decrease in S6K1 phosphorylation in FNIP1-and, to a lesser extent, in FNIPL/FNIP2-suppressed cells. These results suggest that Flcn-FnipL/Fnip2 and Flcn-Fnip1 complexes positively regulate S6K1 phosphorylation and that FnipL/Fnip2 provides an important clue to elucidating the function of Flcn and the pathogenesis of BHD.
Introduction
Birt-Hogg-Dube´(BHD) syndrome is an autosomal dominantly inherited disease characterized by the development of pneumothorax, hair folliculomas and renal tumors (Birt et al., 1977) . In 2002, Nickerson et al. (2002) identified the predisposing gene of BHD (BHD) by positional cloning strategy (Schmidt et al., 2001) . The BHD gene is located on chromosome 17p11.2 and encodes folliculin (Flcn), an evolutionary conserved protein (B67 kDa) with no apparent functional motif (Nickerson et al., 2002) . From the observations of a second somatic inactivation, BHD is thought to be a tumor suppressor (Vocke et al., 2005) .
We have studied the mechanism of multistep carcinogenesis using animal models of hereditary renal carcinoma (RC), such as the Eker rat and the Nihon rat (Hino et al., 2003) . The Eker rat has a germline alteration in the homolog of human TSC2 (Tsc2), a predisposing gene of the tuberous sclerosis complex (Kobayashi et al., 1995) . The Nihon rat has been characterized by earlier development and more aggressive phenotypes of RCs relative to the Eker rat (Okimoto et al., 2000) . Heterozygous Nihon mutant rats develop RCs that mainly show clear-cell histology. Homozygous mutants are embryonic lethal in both Eker and Nihon rats (Okimoto et al., 2004a) . In 2004, we identified a germline mutation in the rat homolog of BHD (Bhd) (Okimoto et al., 2004b) . Subsequently, we demonstrated a suppression of the Nihon rat's phenotypes by transgenic introduction of a wild-type Bhd mini-gene (Togashi et al., 2006) . Thus the Nihon rat became an animal model of BHD (Kouchi et al., 2006) . There is also a dog model available of BHD, which has a missense mutation in the Bhd homolog (Lingaas et al., 2003) .
To better understand the molecular mechanism of BHD/Bhd mutation-associated pathogenesis, the elucidation of Flcn's function is necessary. However, besides its tumor suppressive role, little is known about the physiological activity of Flcn. In a study using Drosophila, involvement of the Bhd homolog in the JAK-STAT and Dpp pathways was expected from the results of RNA interference (RNAi) experiments (Singh et al., 2006) . Baba et al. (2006) identified a novel, evolutionally conserved, human . They demonstrated that the Fnip1 protein also interacts with the AMPK complex and that both Flcn and Fnip1 are phosphorylated by AMPK (Baba et al., 2006) . They also reported that the phosphorylation of Flcn is regulated directly or indirectly by mTOR and that the phosphorylation of S6K1 might be modulated by Flcn expression under certain circumstances (Baba et al., 2006) . Interestingly, a recent report using mutants of the Bhd homolog in fission yeast demonstrated that Bhd-deficiency causes downregulation of Tor2 (van Slegtenhorst et al., 2007) . Conversely, in fission yeast, Drosophila and mammals, a deficiency of Tsc2 homolog activates the rapamycin-sensitive Tor/mTOR pathway (Guertin and Sabatini, 2007; van Slegtenhorst et al., 2007) . These findings suggest that the mTOR pathway in different ways may be involved in various pathogenesis.
Although the mTOR pathway must be important in the pathogenesis of BHD syndrome, it may not be the sole signal transduction system associated with Flcn. We are exploring the function of Flcn by using in vivo (Nihon rats) as well as in vitro experimental systems (Kouchi et al., 2006; Togashi et al., 2006) . In this study, we report the identification and characterization of a novel Flcn-binding protein, FnipL (for Fnip1-Like), which is highly homologous to Fnip1. During the course of the review process of this report, the same Flcn-binding protein was reported as Fnip2 by another group (Hasumi et al., 2008) .
Results
Identification and expression of an FNIP1-related gene, FNIPL In a database search, we noticed the presence of a human gene, KIAA1450 that is highly homologous to FNIP1. KIAA1450 was originally identified in a cDNAsequencing project carried out by the Kazusa DNA Research Institute (Nagase et al., 2000) . KIAA1450 is localized on human chromosome 4q, whereas FNIP1 is on chromosome 5q (HUGE data base, Kazasa DNA Research Institute; http://www.kazusa.or.jp/huge/) (Nagase et al., 2001) . Comparison of deduced aminoacid sequences revealed that KIAA1450 had a putative initiation codon and a subsequent sequence similar to those of the amino-terminal region of the Fnip1 product (Figure 1 ). Therefore, KIAA1450 was thought to cover the full-coding region. The product of KIAA1450 consisted of 1114 amino-acid residues and showed 49.1% sequence identity with human Fnip1 (DQ145719; 1166 residues), through its entire length (Figure 1 and data not shown). In FnipL, there were sequences corresponding to the evolutionary conserved five blocks previously found among Fnip1 orthologs (Figure 1 ) (Baba et al., 2006) . In addition to these five blocks, several other conserved blocks between KIAA1450 and Fnip1 were found (data not shown). From these similarities, we designated KIAA1450 as FNIPL (FNIP1-like) in this study. So far, we have found FNIPL orthologs in various mammals and avians, but not in other vertebrates or the invertebrates, Caenorhabditis elegans and Drosophila melanogaster (data not shown).
Expressions of FNIPL, FNIP1 and BHD in human tissues were examined by Northern blot analysis using gene-specific probes. As shown in Figure 2 , FNIPL showed an expression profile that was relatively similar to those of FNIP1 and BHD. The strongest expression of FNIPL mRNA was observed in the heart with two different bands (7.5 and 6.5 kb). The molecular basis for generating these two bands is currently unknown. A high expression of FNIPL mRNA was also found in placenta and liver, and moderate expression was found in lung, small intestine, kidney and brain. The similarity of expression profiles among those genes suggests that the FnipL and Flcn as well as Fnip1 are functionally related.
Binding of Flcn to FnipL
When N-terminal Myc-tagged full-length FnipL (Myc-FnipL) was expressed in Cos7 cells, it appeared as an B130-kDa protein by western blotting, which coincides with a calculated molecular weight of 122 kDa ( Figure 3a) . As reported previously, several bands of Flcn appeared by western blotting (Baba et al., 2006 Figure 3b ). We have not detected complex formation between Fnip1 and FnipL when they were coexpressed, suggesting that Fnip1 and FnipL independently interact with Flcn (data not shown). Next, we generated an FnipL-specific rabbit polyclonal antibody (Figure 3a ). This antibody did not recognize Fnip1 when it was tested by immunoblotting using transiently expressed proteins. By using this FnipL-specific antibody and anti-Flcn antibody, endogenous Flcn-FnipL interaction in HEK293 cells was confirmed by reciprocal coimmunoprecipitations (Figure 3c ). These results indicate that Flcn and FnipL physically interact with each other and that there are two complexes, Flcn-Fnip1 and Flcn-FnipL, in vivo. Moreover, we noted that coexpression of Flcn with FnipL changes the behavior of Flcn bands on western blotting (Figure 3b ). When the two proteins were coexpressed, the intensity of the slower migrating band of Flcn was increased. In the Flcn-FnipL immunocomplex, the slower migrating band was dominant, suggesting that FnipL binds more tightly to phosphorylated Flcn. These results are consistent with a reported case of Fnip1-Flcn interaction, as we confirmed in our analysis.
To identify the FnipL-binding domain, we used deletion mutants of Flcn lacking the N-terminal region (DSacI; 1-12 and 200-579 aa; Figure 3d , left panel) or C-terminal region (DC; 1-362 aa). Of these, only DSacI could be coimmunoprecipitated with FnipL after transient expression in Cos7 cells, suggesting that the FnipL-binding domain is present in the C-terminal region of Flcn ( Figure 3d , left panel). Reciprocally, we examined the Flcn-binding domain in FnipL using its deletion mutants, such as DNspV (272-1114 aa), DEcoRI (381-1114 aa), DBstPI (544-1114) and DBglII (1-911 aa, Figure 3d , right panel). In the coimmunoprecipitation assay, only DBglII failed to interact with Flcn ( Figure 3d , right panel). This suggests that the C-terminal region of FnipL is needed for binding to Flcn. Together, the interaction between Flcn and FnipL may be mediated mainly by their respective C-terminal domains, as in the case of Flcn-Fnip1 interaction (Baba et al., 2006) .
Localization of FnipL and Flcn
We next analysed the distributions of FnipL, Flcn and Fnip1 by transient expression of epitope-tagged proteins in Cos7 cells. When expressed alone, Myc-FnipL was distributed in the cytoplasm (Figure 4a ). It showed more condensed features around the nucleus. On the other hand, Flag-Flcn was found mainly in the nucleus when solely expressed ( Figure 4a ). However, when MycFnipL and Flag-Flcn were coexpressed they were located together in the cytoplasm in a reticular pattern. As reported previously, Myc-Fnip1 and Flag-Flcn were also located together in the cytoplasm (Figure 4b ). These results demonstrate that FnipL, as well as Fnip1, regulates cytoplasmic distribution of Flcn. We next examined the endogenous distribution of these molecules by cellular fractionation analysis in HeLa cells (Figure 4d ). FnipL and Fnip1 were enriched in the membrane fraction, although a small amount of the latter were found in other fractions. Flcn was also enriched in the membrane fraction, suggesting its colocalization with FnipL or Fnip1. The reticular pattern of Flcn/FnipL and Flcn/Fnip1 found in immunocytochemistry may reflect their association with some membranous components. Interestingly, a significant amount of Flcn was also found in the cytoskeletal fraction. This suggests that there are Flcn molecules free from FnipL-or Fnip1-binding in cells. In our analysis, histone H1 was found in the cytoskeletal fraction in addition to the nuclear fraction. Thus, it should not be excluded that the Flcn component found in the cytoskeletal fraction had been associated with nuclear components.
To ascertain whether the complex formation is necessary for FnipL-regulated cytoplasmic localization of Flcn, C-terminal-truncated FnipL (DBglII) was coexpressed with Flcn and their distributions were analysed. As shown in Figure 4 , DBglII was still located in the perinuclear cytoplasm. However, cytoplasmic retention of Flcn was canceled with C-terminal truncation of FnipL, indicating that their colocalization in the cytoplasm is regulated through the complex formation.
Binding and phosphorylation of FnipL by AMPK
The AMPK complex was also reported as an Flcnbinding component (Baba et al., 2006) . By means of transient expression and coimmunoprecipitation, we also detected an interaction of N-terminal HA-tagged FnipL with N-terminal Myc-tagged a1 subunit of AMPK ( Figure 5 ). When coexpressed with FnipL, the amount of AMPK a1 subunit tended to increase. When the interaction of the AMPK a1 subunit and deletion mutants of FnipL were assessed, both DBstP1 and DBglII showed binding activity, suggesting that the AMPK-binding domain is located between 544-911 aa of FnipL ( Figure 5 ). This region corresponds to the AMPK-binding region of Fnip1, between the evolutionary conserved domains 3 and 4, although the sequence homology is relatively low (data not shown). An in vitro kinase assay revealed that FnipL is phosphorylated by AMPK a1 subunit ( Figure 5 ). Thus, FnipL may receive functional modulation from AMPK similarly to that received by Fnip1.
Suppression of S6K1 phosphorylation by BHD-, FNIPL-or FNIP1 knockdown
To explore the effects of BHD-as well as FNIP1-or FNIPL suppression, we employed RNAi experiments in HeLa cells in which those three genes were expressed. After transfection of siRNAs for BHD, knockdown was assessed by western blot analysis of Flcn and was found to be efficiently accomplished (B85% suppression compared with control cells using b-actin as a control) ( Figure 6 ). As some relationship between Flcn and the mTOR pathway has been demonstrated, we analysed the phosphorylation of S6K1 (Thr389) and found that it was attenuated in the BHD-suppressed cells (mean± s.d. ¼ 0.71±0.17 relative to control cells in phospho-S6K/S6K band ratio, P ¼ 0.04) ( Figure 6 ). Next, we examined the effects of FNIP1 and FNIPL suppression (B85 and B60% suppression, respectively, compared with control cells) ( Figure 6 ). Intriguingly, we also observed a decrease of S6K1 phosphorylation in FNIPL-or FNIP1-suppressed cells (Figure 6 ). FNIP1 suppression significantly reduced S6K1 phosphorylation (0.66 ± 0.09 relative to control cells, P ¼ 0.02). FNIPL suppression also showed subtle reduction in the S6K1 phosphorylation (0.89±0.03 relative to control cells, P ¼ 0.03). Together, these analyses suggest that a 
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Flcn-FnipL or Flcn-Fnip1 complex positively regulates S6K1 phosphorylation. As an implication of the mTOR phosphorylation in the activation of mTORBS6K1 pathway has been suggested, we assessed the phosphorylation status of mTOR (Ser2448) in RNAi analysis. Unexpectedly, we observed a decrease in the total mTOR level after treatment with BHD, FNIPL or FNIP1 siRNAs (Figure 6c ). Accordingly, levels of phosphorylated mTOR (phospho-mTOR) were also decreased ( Figure 6c ). Effects of Flcn-FnipL and FlcnFnip1 complex on mTOR itself were predicted. However, differences in the level of total mTOR and phospho-mTOR were not similar to those of target molecules of RNAi ( Figure 6 and data not shown). Although we could not conclude that Flcn modulates the S6K1 phosphorylation through regulation of mTOR phosphorylation, its function may directly or indirectly affect mTOR.
Discussion
Besides its role as a tumor suppressor, the function of the BHD gene is not clearly understood, but molecular characterization through the identification of binding proteins will provide functional information about Flcn.
To approach a characterization of Flcn Baba et al. ) reported a rapamycin-sensitive phosphorylation of Flcn, which suggests a direct or indirect involvement of mTOR in the regulation of Flcn function. They also reported an Flcn-dependent modulation of S6K1 phosphorylation under particular culture conditions . For example, during amino-acid starvation, the phosphorylation of S6K1 (Thr389) was suppressed in BHD-null cells but not in Fcln expression-reconstituted cells (Baba et al., 2006) . On the contrary, the S6K1 phohsphorylation was retained under serum-starved condition in BHD-null cells but not in Flcn-reconstituted cells (Baba et al., 2006) . Thus various culture conditions may affect the regulatory mechanism of mTORBS6K1 by Flcn. Although our analysis was performed under the amino-acid-sufficient condition, some stress condition during transfection procedure may contribute to the observed changes in S6K1 phosphorylation. More recently, a kidney-specific conditional knockout of mouse Bhd homolog was reported . It resulted in the polycyst formation and elevated mTOR function. In that study, the authors also suggested different responses of mTOR signals to BHD gene status between different experimental systems . Interestingly, fission yeast mutants of the Bhd homolog were more sensitive to rapamycin and resulted in downregulation of the Tor2 complex (TORC1) (van Slegtenhorst et al., 2007) . In Saccharomyces cerevisiae, the LST7 product shows significant homology with Flcn (our unpublished observation), and LST7 mutants exhibit somewhat similar phenotypes to those of LST8, the gene of a TORC1 component (Roberg et al., 1997) . The products of the TSC2 gene (tuberin) and its homologues function in the downregulation of TORC1 (Guertin and Sabatini, 2007) . Thus, at least under certain conditions, Flcn may have the opposite effect of tuberin in terms of mTOR Very recently, FnipL has been identified in a similar homology-based approach and named Fnip2 (Hasumi et al., 2008) . This latter report presented similar results on the Flcn-FnipL/Fnip2 interaction, however Hasumi et al. (2008) also found a binding between Fnip1 and FnipL/Fnip2, whereas we have not identified their strong interaction in forced expression experiments. This difference might be derived from the different experimental conditions and we cannot rule out binding between Fnip1 and FnipL/Fnip2. So far, there are no identified differences between FnipL/Fnip2 and Fnip1 in their functional properties. However, the expression profiles of FNIPL/FNIP2 and FNIP1 mRNAs in human tissues are somewhat different because FNIPL/FNIP2 exhibits higher expression in the liver. In addition, Hasumi et al. (2008) reported different expression profiles of FNIP1 and FNIPL/FNIP2 in renal cancers. The primary structures of Fnip1 and FnipL/Fnip2 are significantly different in the region between the evolutionary conserved domains 3 and 4 (Baba et al., 2006) . This region may be a key to elucidate the functional differences between these two Flcn partners and the two different complexes that include Flcn. Functional differences between those two complexes may provide important clues to understanding the pathogenesis of BHD syndrome and other BHD mutation-associated diseases.
Materials and methods

Plasmid construction
For the transient expression in mammalian cells, the pCAG-GS expression vector was used (Niwa et al., 1991) . N-terminal Flag-, HA-or Myc-tag coding sequence and appropriate multi-cloning sites were introduced using synthetic oligonucleotides. All PCRs and reverse-transcription (RT)-PCRs were carried out by using the Expand High Fidelity PCR System (Roche, Mannheim, Germany) and all subclones were confirmed by sequence analysis. Full-length human BHD cDNA was amplified from a HeLa cell cDNA pool using the primers HBHF1 (5 0 -CCGAATTCAATGC CATCGTGGCTCTCTG-3 0 ) and HBHR1 (5 0 -CCCTCGAGT CAGTTCCGAGACTCCGAGG-3 0 ) and subcloned after digestion with EcoRI and XhoI (at sites underlined in the primer sequences). A partial cDNA clone (KIAA1961) for the Fnip1-encoding gene (FNIP1) and full-length cDNA clone (KIAA1450) for the FnipL-encoding gene (FNIPL) were obtained from Kazusa DNA Research Institute (Kisarazu, Japan). The 5 0 -part of FNIP1 cDNA was amplified using the primers HFPF11 (5 0 -GTCTCGAGCATGGCCCCTACG CTGTTCCA-3 0 ) and HFPR11 (5 0 -TGGGTTAGGGCCAC AGCTTTCATC-3 0 ) and used to construct a full-coding sequence after digestion with XhoI (underline) and HindIII (internal site). For KIAA1450 cDNA, the 5 0 -part of the coding sequence was modified by PCR amplification and re-cloned using the primers HFPF21 (5 0 -GGCTCGAGCATGGCCCC GACCCTGCTCCA-3 0 ) and HFPR21 (5 0 -CCATACAGGTT CAGCTATCCTTGG-3 0 ) after digestion with XhoI (underline) and EcoRI (internal site). Full-length cDNAs for S6K1 and AMPKa1 subunit were amplified from a rat embryonic cDNA pool using the following primers: S6KF1 (5 0 -CGGAATTCG CAGGAGTGTTTGACATAGAC-3 0 ) and S6KR1 (5 0 -CG GGTACCTCATAGATTCATACGCAGGTG-3 0 ) for S6K1; AMPKF1 (5 0 -CGGAATTCGCCGAGAAGCAGAAGCAC GA-3 0 ) and AMPKR1 (5 0 -GGAGATCTTTACTGTGCAA GAATTTTAATTAGAT-3 0 ) for AMPKa1. Amplified cDNAs were subcloned after digestion with restriction enzymes (sites are underlined in primer sequences). Expression plasmids for deletion mutants of Flcn (DSacI and DC) and FnipL (DNspV, DBstPI and DBglII) were constructed by using appropriate restriction sites as indicated in results (see below in Figure 3) . Details of deletion are available upon request.
For in vitro translation, the full-length cDNA for N-terminal Flag-tagged FnipL was amplified using primers HFNIPLF1 (5 0 -ATGGACTACAAGGATGACGATGACAAGGCCCCG ACCCTGCTCCA-3 0 ) and HFNIPLR1 (5 0 -GGGGTACCAA GGAAGAACTGTCCTGAGC-3 0 ) and subcloned into the pTD1 vector (Shimadzu, Kyoto, Japan).
Northern blot analysis
For northern blotting, FNIPL and FNIP1 cDNA fragments showing lowest homology were used as probes. Briefly, a FNIPL cDNA was amplified by PCR from the constructed plasmid using primers FNOF2 (5 0 -CCGAATTCCCAGCAT CAGACGCTTCCT-3 0 ) and FNOR2 (5 0 -TGGACACGACCT CGGACAACTTAAGGG-3 0 ), subcloned and then used as a probe. Similarly, a FNIP1 cDNA was generated from the constructed plasmid cDNA using primers FNOF1 (5 0 -GGG AATTCTTGCAGTCATCCACTCCTTG-3 0 ) and FNOR1 (5 0 -AAGGAGTCGTCCTGGTTTCTCTTAAGCC-3 0 . For BHD, the full-length cDNA was used as a probe. Northern blotting was performed by using a human multiple tissue northern blot membrane (Clontech, Mountain View, CA, USA).
Cell culture and plasmid transfection Cos7, HeLa and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma, St Louis, MO, USA) supplemented with 10% FCS in humidified 5% CO 2 at 37 1C. Plasmids were transfected into Cos7 cells with Fugene 6 (Roche) according to the manufacturer's instructions. Cells were harvested after 48 h incubation. For siRNA transfection, see below (RNAi section).
